BofA On Eli Lilly: Disappointing Q3 Comes In Otherwise Strong 2020

Eli Lilly And Co’s LLY third-quarter results show the persisting impact of COVID-19 and pricing headwinds, according to BofA Securities.

The Eli Lilly Analyst: Geoff Meacham maintained a Buy rating on Eli Lilly with a $180 price target. 

The Eli Lilly Thesis: The downbeat third-quarter results could exert pressure on the company’s stock, Meacham said in the note.

Eli Lilly missed both top- and bottom-line estimates for the quarter.

In the third quarter, the company “saw an impact from pricing pressures (+5% sales growth, +9% volume growth) particularly with Trulicity and increased expenses (+9% y/y), which was driven by COVID-19 development expenses ($125M),” the analyst said.

Lilly's year-to-date growth “still remains strong / differentiated which is a key part of the story, with revenues growing +6% (driven primarily by volume growth),” he said. 

Lilly maintained the 2020 guidance for revenue and non-GAAP earnings, “assuming a rebound in healthcare activity and modest pricing headwinds from patient affordability programs and changes in segment mix,” Meacham said. 

LLY Price Action: Shares of Eli Lilly were down 6.14% at $133 at last check Tuesday.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorEarningsNewsHealth CarePrice TargetReiterationAnalyst RatingsMoversTrading IdeasGeneralBofA SecuritiesGeoff Meacham
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...